Figure 7
β-catenin signaling is dysregulated in the tumor. (A&B) show that total β-catenin is down-regulated in tumor cells. Detection of total β-catenin antigen in WT tail skin (A) and tumor (B) through standard IHC. Note that total β-catenin antigen is down-regulated in the tumor. (C&D) show that phosphorylated β-catenin is down-regulated in tumor cells. Detection of phosphorylated β-catenin antigen in WT tail skin (A) and tumor (B) through standard IHC. Note that phosphorylated β-catenin antigen is down-regulated in the tumor. (E&F) show that active β-catenin is up-regulated in a subpopulation of cells. Detection of active β-catenin antigen in WT tail skin (A) and tumor (B) through standard IHC. Note that active β-catenin antigen is up-regulated in a small population of cells, and slightly down-regulated or unchanged in the majority of tumor cells. (G) double staining found that high levels of stable β-catenin almost exclusively co-localized with a dermal papillae marker (ALP). G'& G" are the split channels of active β-catenin and ALP, respectively. Bar = 40 μm.